Cosyntropin
Cortrosyn, Cosyntropin (cosyntropin) is a protein pharmaceutical. Cosyntropin was first approved as Cortrosyn on 1982-01-01. The pharmaceutical is active against adrenocorticotropic hormone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Cortrosyn, Cosyntropin (discontinued: Cosyntropin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cosyntropin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CORTROSYN | Amphastar Pharmaceuticals | N-016750 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cortrosyn | New Drug Application | 2025-06-17 |
| cosyntropin | ANDA | 2024-02-22 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0834 | Injection, cosyntropin, 0.25 mg |
Clinical
Clinical Trials
55 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adrenal insufficiency | D000309 | — | — | 1 | — | 1 | 6 | 15 | 23 |
| Addison disease | D000224 | — | E27.1 | — | — | — | 2 | 2 | 4 |
| Giant cell arteritis | D013700 | EFO_1001209 | M31.6 | — | — | — | 2 | 1 | 3 |
| Polymyalgia rheumatica | D011111 | EFO_0008518 | M35.3 | — | — | — | 2 | 1 | 3 |
| Hyperaldosteronism | D006929 | — | E26 | 1 | — | — | 1 | 1 | 3 |
| Post-dural puncture headache | D051299 | — | — | — | 1 | — | 1 | — | 2 |
| Hypopituitarism | D007018 | EFO_0001380 | E23.0 | — | — | — | 1 | 1 | 2 |
| Healthy volunteers/patients | — | — | — | — | — | — | 1 | — | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | — | 1 |
| Mitral valve insufficiency | D008944 | — | — | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | — | 2 | 3 |
| Fibrosis | D005355 | — | — | — | — | 1 | — | 2 | 3 |
| Infantile spasms | D013036 | EFO_1000643 | G40.82 | — | — | 1 | — | — | 1 |
| Lecithin cholesterol acyltransferase deficiency | D007863 | — | E78.6 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 1 | — | — | 1 | 3 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | 1 | 2 |
| Duchenne muscular dystrophy | D020388 | EFO_0000429 | — | — | 1 | — | — | — | 1 |
| Muscular dystrophies | D009136 | EFO_0000757 | G71.0 | — | 1 | — | — | — | 1 |
| Headache | D006261 | — | R51 | — | 1 | — | — | — | 1 |
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 4 | — | — | — | 2 | 6 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 3 | — | — | — | 1 | 4 |
| Hyperandrogenism | D017588 | — | — | 3 | — | — | — | 1 | 4 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | 1 | 2 |
| Sleep deprivation | D012892 | — | F51.12 | 2 | — | — | — | — | 2 |
| Overweight | D050177 | — | E66.3 | 1 | — | — | — | — | 1 |
| Diabetic ketoacidosis | D016883 | EFO_1000897 | — | 1 | — | — | — | — | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
| Newborn infant diseases | D007232 | — | — | 1 | — | — | — | — | 1 |
| Adrenal cortex diseases | D000303 | — | — | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | — | 1 | 1 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 1 | 1 |
| Adrenal gland neoplasms | D000310 | EFO_0003850 | C74 | — | — | — | — | 1 | 1 |
| Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | — | — | — | — | 1 | 1 |
| Physiological stress | D013312 | — | — | — | — | — | — | 1 | 1 |
| Baroreflex | D017704 | — | — | — | — | — | — | 1 | 1 |
| Postural orthostatic tachycardia syndrome | D054972 | — | G90.A | — | — | — | — | 1 | 1 |
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | — | — | — | 1 | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | — | 1 | 1 |
Show 14 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cosyntropin |
| INN | tetracosactide |
| Description | Cortrosyn, Cosyntropin (cosyntropin) is a protein pharmaceutical. Cosyntropin was first approved as Cortrosyn on 1982-01-01. The pharmaceutical is active against adrenocorticotropic hormone receptor. |
| Classification | Protein |
| Drug class | tricyclic compounds; atropine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C)C(C)C |
Identifiers
| PDB | — |
| CAS-ID | 16960-16-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2103784 |
| ChEBI ID | 3901 |
| PubChem CID | 16132265 |
| DrugBank | DB01284 |
| UNII ID | 72YY86EA29 (ChemIDplus, GSRS) |
Target
Agency Approved
MC2R
MC2R
Organism
Homo sapiens
Gene name
MC2R
Gene synonyms
ACTHR
NCBI Gene ID
Protein name
adrenocorticotropic hormone receptor
Protein synonyms
ACTH receptor, Adrenocorticotropin receptor, corticotropin receptor, MC2 receptor, MC2-R, melanocortin 2 receptor (adrenocorticotropic hormone), Melanocortin receptor 2
Uniprot ID
Mouse ortholog
Mc2r (17200)
adrenocorticotropic hormone receptor (Q64326)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,840 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
166 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use